Abstract. Metabolic activities in normal cells rely primarily on mitochondrial oxidative phosphorylation (OXPHOS) to generate ATP for energy. Unlike in normal cells, glycolysis is enhanced and OXPHOS capacity is reduced in various cancer cells. It has long been believed that the glycolytic phenotype in cancer is due to a permanent impairment of mitochondrial OXPHOS, as proposed by Otto Warburg. This view is challenged by recent investigations which find that the function of mitochondrial OXPHOS in most cancers is intact. Aerobic glycolysis in many cancers is the combined result of various factors such as oncogenes, tumor suppressors, a hypoxic microenvironment, mtDNA mutations, genetic background and others. Understanding the features and complexity of the cancer energy metabolism will help to develop new approaches in early diagnosis and effectively target therapy of cancer.

Contents

1. Introduction
2. Relationships between glycolysis and OXPHOS are cooperative and competitive
3. Cancer cells have a diversity of energy production pathways
4. Alterations of oncogenes and tumor suppressors drive cancer cells to aerobic glycolysis
5. Conclusion

1. Introduction

Energy consumption from metabolic activities in normal cells relies primarily on mitochondrial oxidative phosphorylation (OXPHOS), which is efficient and generates more adenosine triphosphate (ATP) than glycolysis. However, one of the metabolic features of cancer cells is to avidly take up glucose for aerobic glycolysis. This inefficient pathway for energy production in cancer cells was first described by German scientist Otto Warburg in the 1920s, and is also known as the Warburg effect (1).

Warburg originally proposed that the aerobic glycolysis in cancer cells was due to a permanent impairment of mitochondrial OXPHOS. However, this view is challenged by recent investigations which found that defects of mitochondrial OXPHOS are not common in spontaneous tumors (2) and that the function of mitochondrial OXPHOS in most cancers is intact (1,3-7). Aerobic glycolysis in many cancers is a result driven by various factors, such as activation of oncogenes, loss of tumor suppressors, the hypoxic microenvironment, mitochondrial DNA (mtDNA) mutation and the tissue of origin.

Cancers are extremely heterogeneous diseases and each cancer has its individual metabolic features. Even in a single cancer, its constituent cells are also heterogeneous and metabolic phenotypes vary from one cell to another. Although aerobic glycolysis is often found in malignant tumors, OXPHOS still contributes to energy production in cancers, and may play a major role in energy production in some cancers (8). This article reviews the roles of glycolysis and OXPHOS in the energy metabolism of cancers.

2. Relationships between glycolysis and OXPHOS are cooperative and competitive

Before the introduction of free oxygen into the atmosphere, organisms on earth rely on glycolysis as an energy source. However, with the increase of atmospheric oxygen, cells begin to rely primarily on OXPHOS to produce energy since it generates more ATP per metabolite than the glycolytic pathway.

However, glycolysis, an ancient energy production pathway preserved in evolution, still affects energy metabolism in certain human organs and tissues, such as the brain, liver and muscle (9,10), and is also a major energy production pathway in anaerobic bacteria. In fact, glycolysis and OXPHOS are tightly coupled and serve as a molecular interconversion system. The process of glycolysis is carried out in the cytoplasm and only produces two ATPs. Pyruvate, the end product of glycolysis, is a fuel for OXPHOS. Under aerobic conditions pyruvate enters the mitochondria to be oxidized to acetyl CoA which combines with oxaloacetate to start the tricarboxylic acid cycle.
acid (TCA) cycle and OXPHOS, which can produce 36 ATPs. Under anaerobic conditions, pyruvate is reduced to lactate by lactate dehydrogenase (LDH-A) in the cytoplasm and then lactate is excreted into the extracellular space through monocarboxylate transporters (MCTs).

Since energy production is a response to energy demand in the cell, the ATP yield varies depending on cellular conditions and the microenvironment. Mammalian cells rely primarily on both glycolysis and OXPHOS to produce ATP at present. However, the contribution ratio of glycolysis versus OXPHOS for the total ATP yield varies in different cells, growth states and microenvironments. In normal conditions, the cell metabolism consumes energy, of which 70% is supplied by OXPHOS. In hypoxia, however, glycolysis becomes enhanced to compensate for the weakened function of OXPHOS. Therefore, glycolysis and OXPHOS cooperate to maintain the cellular energetic balance. Supposing the total ATP is a constant, if the function of OXPHOS is weakened, the function of glycolysis must be enhanced in order to maintain a balance of energy. In contrast, if the function of OXPHOS is normal, it will regulate glycolytic activity via different pathways to maintain a balance of energy (11). In contrast to normal cells, most cancer cells use glycolysis as a means of energy production whenever normoxia or hypoxia occurs, which is referred to as aerobic glycolysis (1).

### 3. Cancer cells have a diversity of energy production pathways

Cancer cells are different from most normal tissues in the energy metabolism and they take up glucose and glutamine at a high rate for aerobic glycolysis. In addition, cancers are extremely heterogeneous and each cancer is different in tissue origin and metabolic phenotype (3). Even in a single cancer, its constituent cells vary in metabolic phenotype (12). It is worth mentioning that metabolic phenotypes in cancer are plastic, and cancer tissues exhibit greater plasticity than normal tissues (13). Cancer cells may change their metabolic phenotypes to adapt to microenvironmental changes and the results of these changes give a selective advantage to cancer cells under the unfavorable environment (14,15).

**Glycolysis versus OXPHOS.** Due to their different origin and differentiation, not all cancers rely primarily on glycolysis, which contributes to total ATP at a rate of 1-64% in cancer cells (8). For example, Suganuma et al examined the energy metabolism of four leukemia cell lines using glycolysis inhibitor 2-deoxy-D-glucose (2-DG) and OXPHOS inhibitor oligomycin (16). They found that NB4 cells were more sensitive to 2-DG than the three other cell lines, hence they regarded NB4 as a ‘glycolytic’ leukemia cell line. Alternatively, THP-1 cells were resistant to 2-DG and sensitive to oligomycin, and were regarded as an ‘OXPHOS’ leukemia cell line (16). These results suggest that energy metabolic pathways are different in various cancers. We should first examine energy metabolic pathways in cancer cells when considering energy metabolism as a target for cancer therapy in order to obtain good therapeutic results.

Warburg considered that aerobic glycolysis in cancer cells was irreversibly impaired in its mitochondrial function. This view is challenged by recent investigations which found that the function of mitochondrial OXPHOS in many cancers is intact (1,3-7). Certain authors consider that the Warburg effect in cancer is due to enhanced glycolysis suppressing OXPHOS rather than defects in mitochondrial OXPHOS. If glycolysis is inhibited in cancer cells, the function of mitochondrial OXPHOS can be restored (4,17-19). For example, Fantin et al observed that when LDH-A was suppressed in cancer cells, OXPHOS function could be enhanced to compensate for reduced ATP by inhibited glycolysis. This observation suggests that most cancer cells reserve the capacity to produce ATP by OXPHOS. The glycolytic phenotype in cancer cells is due to OXPHOS being suppressed by active glycolysis rather than defects in mitochondrial function. Furthermore, they also found that proliferation and tumorigenicity of cancer cells were inhibited when LDH-A activity was suppressed, suggesting that enhanced OXPHOS is still not sufficient to meet the requirement of cancer growth and that LDH-A is a target of cancer therapy (4).

Since the glycolytic contribution to total ATP production does not generally exceed 50-60% (8), OXPHOS still substantially contributes to ATP production in tumor cells. Although four human malignant tumor cell lines (HL60, HeLa, 143B and U937) are cells which rely on OXPHOS to support the growth of cells (20), this phenotype is altered under hypoxia. For example, the OXPHOS contribution to total ATP production is normally 79 and 91% in cervical carcinoma HeLa cells and breast carcinoma MCF cells, respectively. This contribution, however, is reduced to 29 and 36% in hypoxia, respectively (21), suggesting that the glycolytic phenotype in cancer cells is primarily caused by hypoxia. In their retrospective review, Moreno-Sánchez et al point out that although glycolysis plays an important role in cancer energy metabolism, a considerable amount of cancers use OXPHOS as a pathway of energy production or a mixture of glycolysis and OXPHOS (17). In some cases, the function of OXPHOS in cancer cells is even higher than in adjacent stromal cells (22). Researchers from Singapore recently isolated intact mitochondria from human ovarian and peritoneal cancer tissues, which exhibited the specific activities of succinate, malate and glutamine dehydrogenases, and had the capacity of OXPHOS. The cells produced ATP, but in lower amounts than the human skeletal muscle (6).

Smolikova et al (19) proposed four waves of metabolic regulation during carcinogenesis. Wave 1: cancer stem cell (CSC) transformation, primarily due to oncogene-mediated signaling; Wave 2: hypoxia, inducing hypoxia-inducible factor (HIF), AMP-activated protein kinase (AMPK) and NF-κB signaling. In waves 1 and 2, the cell metabolism highly favors glycolysis and inhibits OXPHOS due to the oncogenic and hypoxic controls of gene reprogramming, i.e., the classic Warburg phenotype. Wave 3: aglycemia, nutrient shortage due to the high proliferation rate during malignancy. In this wave, the function of mitochondrial OXPHOS is partially restored due to gene reprogramming via the LKB1-AMPK-p53 pathway and/or the PI3K-Akt-mTOR pathway. Myc-mediated glutaminolysis is also involved in this process. Wave 4: mitochondria revival, retrograde signaling from revitalized mitochondria may constitute this wave of gene reprogramming. This working hypothesis indicates that the Warburg
Recently showed that the rate-limiting enzyme in glycolysis and pyruvate kinase 1 (PK1), and glycolysis will be inhibited. The high concentration of ATP will inhibit the mitochondrial function which is suited to the energy demands of rapid proliferation tissues such as cancer and embryonic tissues (11). Generally speaking, rapid proliferation tissues rely more on glycolysis for ATP production whereas differentiation tissues rely primarily on OXPHOS for energy production (13,31). If using glycolysis inhibitor 3-bromopyruvate (3-BP) treats tumors, it is more efficient for rapid growth of tumors than slow growth of tumors. iii) Hypoxia is often observed in cancer tissues, and glycolysis offers growth advantage of cancers under this hypoxic environment (4). Glycolysis produces lactate which is released into the extracellular space. An acidic microenvironment provides a growth advantage to cancer tissues over normal tissues and enhances the invasion and metastasis of cancer cells (32,33). In addition, lactic acidosis inhibits glycolysis and favors aerobic respiration as a means of energy generation (14). iv) Due to the decrease of mitochondrial OXPHOS, less reactive oxygen species (ROS) are generated, which are cytotoxic to cancer cells (34,35).

Although cancer cells may retain OXPHOS function, it does not mean that cancer cells have no defects in mitochondrial respiration. Enhanced glycolysis in certain cancers is due to an impairment of mitochondrial function (36,37), including decreased expression of mitochondrial oxidative enzymes and transporters, truncated TCA cycle, a lowering in the amount of mitochondria per cell and defective respiratory chain, an increased amount in the natural inhibitors of the mitochondrial ATP synthase and a higher sensitivity of mtDNA to oxidative stress (17,38).

Certain cancer cells may use glutamine as energy fuel. Although it is widely accepted that glucose is the dominant energy fuel for most cancers, it is not the only one. Glutaminolysis may be an alternative pathway for energy production in certain cancers since it is known that elevation in glutamine consumption is frequently observed in cancer (39,40). In 1979, Reitzer et al reported that glutamine, not sugar, was the major energy source for cultured HeLa cells (41). Since then, several reports have shown that glutamine may be used as the energy fuel for cancer cells (42-45). In contrast to glucose, glutamine as an energy fuel is only observed in a few cancer cell lines (27) and plays an important role in compensating for the shortage of glucose in some cases.

After entering cells via membrane transport ASCT2, glutamine is hydrolyzed to glutamate and ammonia by glutaminase (GLS). Glutamate combines with cysteine and glycine to form reduced glutathione (GSH) which is found in all human cells. GSH is involved in regulating the redox state and is a major antioxidant in cells.

Glutamate may also be converted into α-ketoglutarate (α-KG) and enters the TCA cycle to supply intermediates and energy for cell growth. It is particularly useful in the truncated TCA cycle which cannot efficiently use glucose to generate energy (2). This process provides fuel for the passive TCA cycle due to a lack of isocitrate (2,7,39,46-48). Therefore, it also demonstrates that cancer cells are able to use OXPHOS for ATP production.

Glutamine not only supplies energy in certain cancer cells, but also provides precursors (such as citrate) for the synthesis of lipids. For example, Mullen et al recently showed that tumor cells with mutations in complex I or III of the electron...
transport chain (ETC) used glutamine-dependent reductive carboxylation as the major pathway of citrate formation, suggesting that glutamine supports tumor growth in various pathways in defective mitochondria (49).

It is worth mentioning that elevation of glutamine consumption in cancer cells is closely related to Myc activation (see below). When mouse embryonic fibroblasts are introduced by the Myc gene, the transfected cells will increase glutaminolysis. If RNA interference (RNAi) downregulates Myc expression, the tumor cells will reduce their dependency on glutamine (39). Other research also supports the effects of Myc on glutaminolysis. For example, human fibroblasts in medium without glucose will die. This process is not related to Myc activity and occurs by a mechanism other than apoptosis. However, these cells in medium without glutamine induced Myc-dependent apoptosis (43), suggesting that interfering with glutaminolysis may obtain better therapeutic effects than interfering with glucose in certain cancers. In fact, the situation is more complex in vivo. Cells also obtain energy through other pathways, such as fatty acid, lactate and ketone oxidation, as well as unidentified sources (22,23,42,50).

4. Alterations of oncogenes and tumor suppressors drive cancer cells to aerobic glycolysis

Cancer cells still use aerobic glycolysis, despite it being an inefficient way to generate ATP. Increasing evidence shows that the alterations of oncogenes and tumor suppressors in tumorigenesis play a key role in aerobic glycolysis of cancer (Fig. 1) (51-53).

Oncogene Ras mutations are often found in many types of human cancers and drive the metabolic phenotype of cancer cells toward aerobic glycolysis (54). Ras activates the mammalian target of rapamycin (mTOR) via the PI3K-Akt-mTOR signaling pathway and mTOR promotes glycolysis through inducing HIFs (34,55-58). HIFs, induced transcription factors to facilitate cellular adaptation to hypoxic environments, play critical roles in shifting from the OXPHOS to the glycolytic phenotype in cancer (Fig. 1) (34,55,59,60). HIFs are heterodimers consisting of an oxygen-labile α subunit and a stable β subunit. In mammals, HIFs have three isoforms: HIF1, HIF2 and HIF3. HIF1 is ubiquitously expressed in all cells, whereas HIF2 and HIF3 are selectively expressed in certain tissues (61). As a transcription factor, HIF1 regulates over one hundred different genes, including vascular endothelial growth factor (VEGF), hepatocyte growth factor receptor (c-Met), erythropoietin (epo), transforming growth factor-α (TGF-α), platelet-derived growth factor-β (PDGF-β) and glucose transporter GLUT1, and influences many cellular activities, including angiogenesis, glycolysis and cell survival.

In energy metabolism, HIF1 induces GLUT1 and GLUT3 expression and upregulates 9 of the 10 enzymes that function in glycolysis (52). It also inhibits the conversion of pyruvate to acetyl-CoA via the activation of pyruvate dehydrogenase kinase 1 (PDK1), leading to a decrease of mitochondrial OXPHOS.

Recent studies show that mTOR upregulation of pyruvate kinase M2 (PKM2) is critical for aerobic glycolysis and tumor growth (62). M type pyruvate kinase (PK) has two isoforms: PKM1 and PKM2. PKM1 is expressed in most adult tissue, whereas PKM2 is only expressed in embryonic and proliferating tissues. When cells are transformed, PKM1 expression is inhibited, and PKM2 expression is restored. The metabolic switch from OXPHOS to aerobic glycolysis in tumor tissues is considered to be a shift from PKM1 to PKM2 expression (63). mTOR upregulates PKM2 via HIF1 and Myc (62), being consistent with Myc upregulation of glycolysis. Myc can also upregulate the PKM2 expression via polypyrimidine tract-binding protein (PTB), heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and hnRNP A2 (64). Notably, new data also show that PKM2 may be a strong partner for HIF1 transcription activity in hypoxia, and since PKM2 gene transcription is also activated by HIF1, this suggests that PKM2 participates in a positive feedback loop of HIF1 transcription in cancer cells (65). However, another recent study showed no evidence of a shift from PKM1 to PKM2 expression during tumorigenesis. Researchers found that PKM2 was the prominent isoform in all analyzed cancer samples and cell lines but PKM2 was also found in matched control tissues (66). Therefore, whether a shift from PKM1 to PKM2 expression occurs during tumorigenesis remains to be clarified.

In addition to mediating HIFs, mTOR directly upregulates the basic glycolytic processes, from glucose uptake to lactate formation (56,58,67). When glucose uptake goes beyond that required by cancer cells, it results in pyruvate being reduced to lactate which is excreted into the extracellular space.

The oncogene Myc, frequently overexpressed in human cancers, is a master transcription factor which regulates over 15% of human genes, including cell cycle, metabolism (glucose, glutamine, protein and lipid), ribosome biogenesis, RNA (miRNA, tRNA and rRNA), mitochondrial biogenesis, apoptosis and transformation. Myc stimulates the Warburg effect in cancers in two aspects (46,48). Firstly, Myc upregulates the expression of glucose transporter GLUT and LDH-A (1); and secondly, Myc promotes glutamine metabolism, including glutamine uptake and glutaminolysis, as well as unidentified sources (22,23,42,50).
glutaminolysis to provide energy for use by cells (39). The upregulation of the glutamine metabolism by c-Myc is related to microRNA-23a/b (miR-23a/b), which targets GLS. c-Myc stimulates the glutamine metabolism and cell proliferation by repressing miR-23a/b (68).

Compared with Ras, which regulates glycolysis via the PI3K-Akt pathway, increase of the glutamine metabolism by Myc does not depend on the PI3K-Akt pathway. Using the PI3K-Akt pathway inhibitors suppressed the glucose metabolism, but not the glutamine metabolism, suggesting that the oncogenes Ras and Myc cooperatively maintain transforming cells via the two key nutrients glucose and glutamine, complementing each other (39). In order to engage in replicative division, a cell must duplicate its genome, proteins and lipids and assemble the components into daughter cells; in short, it becomes a factory for macromolecular biosynthesis. These activities require that cells take up extracellular nutrients such as glucose and glutamine and allocate them into metabolic pathways that convert them into biosynthetic precursors. Many intermediates from glycolysis, truncated TCA and glutaminolysis are used in cell biosynthesis during the cancer cell metabolic switch to glycolysis by Ras and Myc (40,57).

In addition, HIF1 also binds to a DNA motif in the promoter of Myc and enhances the transcription of Myc (Fig. 1). HIF1 cooperates with c-Myc to promote aerobic glycolysis by induction of hexokinase 2 (HK2), converting glucose to glucose 6-phosphate, and PDK1, a negative regulator of pyruvate dehydrogenase (PDH) (69).

Tumor suppressor p53, one of the most common gene mutations in human cancers, is a transcription factor and widely regulates diverse biological functions, including the cellular energy metabolism. It plays a pivotal role in balancing between glycolysis and OXPHOS (70,71). p53 combined with HIF1 and c-Myc has been described as the ‘triad’ of transcription factors responsible for the glycolytic phenotype in cancer (Fig. 1) (1,69,72).

In normal conditions, p53 downregulates the expression of GLUT1, GLUT4 and HK2, and upregulates the expression of TP53-induced glycolysis and apoptosis regulator (TIGAR) and synthesis of cytochrome c oxidase 2 (SCO2) (Fig. 2) and apoptosis-inducing factor (AIF) (73). Thus, the basic effects of p53 on the cellular energy metabolism are to inhibit glycolysis and promote OXPHOS (70,73). TIGAR, an enzyme that decreases the levels of fructose-2, 6-bisphosphate (Fru-2, 6-P2) by dephosphorylating, inhibits glycolytic activity (74). Fru-2, 6-P2 is an important allosteric effector (+) of PFK1, one of key regulatory enzymes of glycolysis (Fig. 2). SCO2 facilitates the assembly of cytochrome c oxidase complex in the mitochondrial ETC complex IV. AIF is essential for ETC complex I function (75). p53 deficiency leads to reduced SCO2 and AIF activity, resulting in mitochondrial OXPHOS impairment (76).

Moreover, p53 is also a potent negative regulator of HIF1α (Fig. 1). Activation of p53 blocks the accumulation of HIF1α in normoxia and hypoxia (77), and inhibits HIF1 by inducing microRNA-107 (78).

The p53-deficient cells produced significantly higher levels of lactate, indicating a shift from OXPHOS to glycolysis in energy production. For example, glycolysis contributing to the total amount of ATP is 40% in human colon cancer cell line HCT116 with wild-type (+/+), rising to 66% in homozygous (-/-) p53 (71). Inactivation of p53 leads to favor aerobic glycolysis in many aspects, including increase of glucose uptake and HIF-1α, and decrease of TIGAR, SCO2 and AIF expression. Moreover, mutant p53 also increases the activity of two other glycolytic enzymes, HK2 and phosphoglycerate mutase (PGM), catalyzing 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG) (71,73,79).

5. Conclusion

Cancers have different metabolic phenotypes of energy for several reasons. First, cancers are heterogeneous diseases and their genetic heterogeneity determines metabolic hetero-
neity (15). Even from a single cancer, its constituent cells are also heterogeneous and reflect differences in metabolic phenotype from one cell to another. The different subclones within a cancer benefit each other in the metabolism and form a metabolic symbiont (26). This phenomenon is not cancer-specific, and cancer cells also use other physiological mechanisms to support their rapid growth. Second, cancer cells continuously reprogram to adapt to environmental pressures and alteration of growth conditions. The result is that the ratio between glycolysis and oxidative phosphorylation to yield total ATP, are continuously changing. The result of these changes is that the unfavorable environment and fatty acid to yield total ATP, are continuously changing.

growth conditions. The result is that the ratio between glycolysis reprogram to adapt to environmental pressures and alteration of metabolic symbiont (26). This phenomenon is not cancer ‑specific, type from one cell to another. The different subclones within a cell hierarchy in metastatic cancer. Mitochondrion 10: 584-588, 2011.


